Compounds > enzastaurin
Page last updated: 2024-09-05

enzastaurin and ro 31-8220

enzastaurin has been researched along with ro 31-8220 in 1 studies

Compound Research Comparison

Studies
(enzastaurin)		Trials
(enzastaurin)		Recent Studies (post-2010)
(enzastaurin)		Studies
(ro 31-8220)		Trials
(ro 31-8220)		Recent Studies (post-2010) (ro 31-8220)
1885299587164

Protein Interaction Comparison

ProteinTaxonomyenzastaurin (IC50)ro 31-8220 (IC50)
Ribosomal protein S6 kinase alpha-5Homo sapiens (human)0.008
Serine/threonine-protein kinase 10Homo sapiens (human)0.099
cAMP-dependent protein kinase catalytic subunit alphaBos taurus (cattle)0.9
Serine/threonine-protein kinase pim-1Homo sapiens (human)0.01
Protein kinase C alpha typeHomo sapiens (human)0.033
Glycogen synthase kinase-3 betaRattus norvegicus (Norway rat)0.0068
Ribosomal protein S6 kinase beta-1Homo sapiens (human)0.015
Mitogen-activated protein kinase kinase kinase 8Homo sapiens (human)9.95
Glycogen synthase kinase-3 betaHomo sapiens (human)0.0116
Ribosomal protein S6 kinase alpha-3Homo sapiens (human)0.01
Protein kinase C beta typeRattus norvegicus (Norway rat)0.01
Homeodomain-interacting protein kinase 1Homo sapiens (human)0.621
NAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)0.875
Mitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)0.0529
NAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)3.9
Serine/threonine-protein kinase VRK1Homo sapiens (human)0.743
NAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)3.7
Serine/threonine-protein kinase TBK1Homo sapiens (human)0.656

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bach, S; Cahill, MM; Marchand, P; McCarthy, FO; O'Shea, KD; Pierce, LT; Robert, T; Ruchaud, S; Winfield, HJ1

Other Studies

1 other study(ies) available for enzastaurin and ro 31-8220

ArticleYear
Synthesis and anticancer activity of novel bisindolylhydroxymaleimide derivatives with potent GSK-3 kinase inhibition.
    Bioorganic & medicinal chemistry, 2018, 08-07, Volume: 26, Issue:14

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Glycogen Synthase Kinase 3; Humans; Maleimides; Molecular Structure; Protein Kinase Inhibitors; Structure-Activity Relationship

2018